IXICO plc CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strategy for innovation, leadership, and growth in the neurodegenerative disease space. Goorden outlined how IXICO’s precision medicine platform, TTNx, uses AI to analyse imaging data for pharmaceutical and biotech companies developing new drugs, particularly in Alzheimer’s, Parkinson’s, and Huntington’s diseases. The CEO emphasised that the company's focus remains on expanding its portfolio, enhancing analytics within existing programs, and tapping into emerging opportunities like blood-based biomarkers. “You may know that IXICO is an absolute leader in especially rare diseases, Huntington's disease and so on, but we've really seen that expansion of portfolio,” Goorden said. He also discussed the company’s strategic pillars: Innovate, Lead, and Scale. This includes integrating new algorithms, raising the company’s voice in the global precision medicine market, and strengthening its US operations to support further growth. Goorden noted that IXICO is seeing increased engagement from partners seeking FDA approvals who rely on gold-standard imaging for validation. He also mentioned the company’s recent hires and commitment to driving more partnerships throughout 2025. Visit Proactive’s YouTube channel for more exclusive interviews and insights. Don’t forget to like this video, subscribe to our channel, and turn on notifications for future updates. #IXICO #BramGoorden #PrecisionMedicine #NeurodegenerativeDiseases #AlzheimersResearch #ParkinsonsDisease #DrugDevelopment #AIinHealthcare #Biomarkers #ClinicalTrials #HealthcareInnovation #FDAapproval

First Phosphate Corp. CEO John Passalacqua joined Steve Darling from Proactive to express strong support for the growing political recognition of Quebec’s clean, igneous phosphate reserves, following a notable mention during the recent Canadian Federal Election Debate in Montreal. During the debate, Bloc Québécois candidate Yves-François Blanchet emphasized the strategic importance of Quebec’s phosphate resources, stating that the province "has probably the most important clean phosphate reserves in North America," specifically in Saguenay–Lac-Saint-Jean. He highlighted the opportunity to fully leverage these assets, noting that Port Saguenay could serve as a key infrastructure hub to support development and export. Passalacqua called the public acknowledgment "a major milestone," saying it demonstrates broadening political support for phosphate’s role in advancing Canada’s energy, technology, and manufacturing sectors. “It’s encouraging to see phosphate move into the national conversation,” he said. “This validates our ongoing work to create a fully integrated and resilient North American supply chain for phosphate-based lithium iron phosphate (LFP) batteries—essential for the future of automation, robotics, AI, and clean energy storage.” The company's focus on clean, high-purity igneous phosphate positions it uniquely to serve these emerging markets. With over 1,000 sq. km of claims in Quebec, First Phosphate is building a vertically integrated LFP ecosystem—from mining through to battery-grade materials—to strengthen supply chain sovereignty and security. The significance of phosphate has also been officially recognized, with the mineral added to Quebec’s Critical Minerals List in January 2023, and to the Canadian federal Critical Minerals List in June 2024. #proactiveinvestors #firstphosphatecorp #cse #phos #otcqb #frspf #phosphate #CriticalMinerals #BatteryMaterials #LFPCathode #FirstPhosphate #CanadaMining #GreenEnergy #SupplyChain #QuebecMining #EVBatter

Ilika PLC CEO Graeme Purdy talked with Proactive's Stephen Gunnion about the company’s latest progress in scaling up its Goliath solid-state battery technology. The discussion focused on improved results from Ilika’s collaboration with the UK Battery Industrialisation Centre (UKBIC). Purdy said: “We’re seeing an improved yield out of the industrialised process,” adding that this reduces waste and lowers costs. More notably, the batteries produced via UKBIC’s process outperform those created on Ilika’s pilot line, showing stronger power density and faster charge-discharge capabilities. Purdy confirmed the project’s shift from process to performance, marking the completion of a £2.7 million grant-supported programme funded by the Advanced Propulsion Centre. He also referenced recent government pledges of £2 billion to back automotive electrification, suggesting that future grant funding could help support Ilika’s product roadmap without shareholder dilution. Looking ahead, Ilika plans to release its P1.5 prototypes—10Ah cells—later this summer. Once enough testing data is gathered, the batteries will be shared with OEMs and Tier 1 suppliers enrolled in its evaluation programme. Purdy also teased the release of 50Ah P2 prototypes by year-end, built on insights gained from the Faraday Battery Challenge. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #IlikaPLC #GoliathBattery #SolidStateBatteries #EVTechnology #BatteryInnovation #UKBIC #AutomotiveElectrification #AdvancedPropulsion #BatteryManufacturing #GraemePurdy

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed the company's newly-announced research license agreement with Catalent with Proactive's Stephen Gunnion. Buck shared insights into Lisata’s preclinical evaluation of certepetide using Catalent’s SMARTag antibody-drug conjugate (ADC) platform.. She explained that Catalent would assume all R&D costs, while Lisata provides consulting and stands to receive both upfront and potential milestone payments. Certepetide is described as a unique cyclic non-amino acid peptide, designed to bind to receptors commonly found on solid tumors. Upon binding, it transforms to activate a transport mechanism that boosts therapeutic penetration. "It can work with current therapies and emerging therapies," Buck said, emphasizing its compatibility and favorable safety profile. Buck further discussed the growing relevance of ADCs in oncology. She described ADCs as “biological missiles,” targeting tumors while minimizing harm to healthy tissues. When combined with certepetide, ADCs benefit from deeper tumor penetration and potential immunomodulation, making treatment more effective. The company expects initial data from this collaboration before the end of Q2 2025. Positive results could lead to a deeper relationship with Catalent. Visit Proactive's YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #LisataTherapeutics #KristenBuck #Certepetide #AntibodyDrugConjugates #ADC #OncologyInnovation #CancerResearch #Catalent #BiotechNews #TumorTargeting #ImmunoOncology #SMARTagPlatform